Loading data for CCCC — first visit, this takes a few seconds.

Alert

C4 Therapeutics Inc. (CCCC)

NasdaqGS: CCCC · Real-Time Price · USD

4.10

-0.14 (-3.30%)

At close: Aug 28, 2026, 11:45 AM

3.85

+0.00%

After-hours: 6:09 PM

The price, the headline numbers and the latest news, in one place.

-3.30% (1D)

Bid	3.04
Market Cap	473.65M
Revenue (ttm)	35.04M
Net Income (ttm)	-101.42M
	2.95
	-0.91
	n/a
	-3.86
P/B (ttm)	1.91
P/S (ttm)	13.52
Earnings Date	Nov 5, 2026

Ask	5.29
Volume	1,987,961
Avg. Volume (20D)	3,098,931
Open	4.25
Previous Close	4.24
Day's Range	4.09 - 4.30
52-Week Range	1.69 - 5.17
Analyst	n/a
Price Target	n/a
Dividends	n/a
Ex-Dividend Date	n/a

About CCCC

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology product candidate, CFT8919, an orally bioavailable, ...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Oct 2, 2020

Employees 104

Stock Exchange NasdaqGS

Ticker Symbol CCCC

Website https://www.c4therapeutics.com

Full Company Profile

Financial Performance

In 2025, C4 Therapeutics's revenue was 35.95M, an increase of 1.02% compared to the previous year's 35.58M. Earnings were -104.99M, a decrease of -0.31%.

Financial Statements

Earnings Surprise

C4 Therapeutics has released their quarterly earnings on Aug 11, 2026:

Revenue of $6.15M misses estimates by $0, with -15.00% YoY decline.
EPS of -0.18 exceeds estimates by 0.05, with 51.35% YoY growth.

Next Earnings Release

C4 Therapeutics Inc. is scheduled to release its earnings on Nov 5, 2026, before market opens.
Analysts project revenue of ... Upgrade

News

1 week ago · Zacks

Are You Looking for a Top Momentum Pick? Why C4 Therapeutics, Inc. (CCCC) is a Great Choice

Does C4 Therapeutics, Inc. (CCCC) have what it takes to be a top stock pick for momentum investors? Let's find out.

2 weeks ago · Zacks

C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Tops Revenue Estimates

C4 Therapeutics (CCCC) delivered earnings and revenue surprises of +21.74% and +10.68%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

1 month ago · Zacks

Is C4 Therapeutics (CCCC) Stock Outpacing Its Medical Peers This Year?

Here is how C4 Therapeutics, Inc. (CCCC) and Illumina (ILMN) have performed compared to their sector so far this year.

1 month ago · Zacks

C4 Therapeutics, Inc. (CCCC) Is Up 2.65% in One Week: What You Should Know

Does C4 Therapeutics, Inc. (CCCC) have what it takes to be a top stock pick for momentum investors? Let's find out.

1 month ago · Insider Monkey

C4 Therapeutics (CCCC) Gains Over the Past Month, Can It Go Higher?

C4 Therapeutics, Inc. (NASDAQ:CCCC) has gained roughly 16% over the past month, mainly driven by positive phase 1 clinical trial data for Cemsidomide. The data was presented on June 11, following whic...

Page 1 of 2

C4 Therapeutics Inc. (CCCC)